Filed by the Registrant ☒
|
| |
Filed by a Party other than the Registrant ☐
|
☐
|
Preliminary Proxy Statement
|
☐
|
Confidential, for Use of the Commission Only (as permitted by
Rule 14a-6(e)(2))
|
☐ |
Definitive Proxy Statement
|
☒ |
Definitive Additional Materials
|
☐
|
Soliciting Material under §240.14a-12
|
ARBUTUS BIOPHARMA CORPORATION
|
(Name of Registrant as Specified in its Charter)
|
|
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
|
☒ |
No fee required
|
☐
|
Fee paid previously with preliminary materials
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1)
and 0-11
|
D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0, PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#044%]@8&!A8&)P8W!D@&
M609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-
M^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC
M',P<]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A( &YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M](-7@[J$'82 A..%1X6KA@Z& -CV/=**\ET_XE75N 3TNR53BG>R"LBZ\)6ET-K0H #GY!L/YI@_ATK7HI*36PW%/ L'_7&/\ ] %1_P NUZE_\O7Z
M?J:-<;\4_P#CU3_KLO\ Z ]=E7&_%/\ X]4_Z[+_ .@/11_B(*_\.1H^.+ S
M6_VB/_6VS"1#\N1M.6^\.F.<=R!UZ5K:5J U&)+A<8D4' .<$CD9]CP?<5;K
M@].UC_A&$NK(DLUN=\>26^63:%!X4#!92V",EC@<A4@@XX
MZBG*$H[H(SC+9DE%5M0U!-/0SRG:BXR<$]2 . ">IK'_ .%@6/\ SU_\+9$2TF,F-OED#(S
M\QX3_P >Q@]CS6D9)M*QE*,E%N_Y&G;7"W*K*ARKJ"#TR",@\UF>(?$B:*%!
M5GDE)"(@Y)'OVY('<\\ U'X*C=+.$29W;XC)P6.QB?S8_3
M) XJ/XBVHO)K.%L[9)&4XZX9HP<5-I?_ "%[C_KBO\HJ/''_ !]6/_7;_P!G
MCK1/]Y%^7Z&37[N2\_U.PCC$0"* %4 8 Z "N-O(_L^L1%,CS8B7P3SA7
M S_WRO'3(SUKM*XW5/\ D+V__7%OY2UE2W?HS6MM'U1H_$#_ (\9?^ ?^C%K
M0\.?\>L'_7&/_P! %4?'D9DLI0H).%/ SP'4D_@!D^U6O"MPMQ:0LIR!$H_%
M1M(Y]"#1_P NOG^@?\O?E^IA?%/_ (]4_P"NR_\ H#UV5<+\5;]1%';?QE]^
M.. H*\\YY)XXYP?2M+XB:G)86V8B59Y%7<"0P&"W!!&/NX^F:KD
./\ CZL?^NW_ +/'795QOCC_ (^K'_KM
M_P"SQUV5$_@C\_S%#XY_+\CC=4_Y"]O_ -<6_E+1\4_^/5/^NR_^@/1JG_(7
MM_\ KBW\I:/BG_QZI_UV7_T!ZTC\3_ #,Y?!4]?\CJ=.L%T^-;>/[J* .F
M?J<
#Z*P'/ ^8DG QSFNFHIQDXBE!2W.1U+
MX=1W2%1(WF,X8R2_O'(52H7.5XY_09S@8Z74-/34$,$HW(V,C)'0@CD$'J*L
MT4.I)VUV!4XJ^FYS,'A2>U'DQ74@AX&TJK.!@ @2'[O3C &WTSU='X#MXVCE
MRY>*0ON+ L[$@_,2O/3MCN>I)KI**?M9"]E'L9WB#2/[7@>UW;=^WG&<88-T
MR/3UJQIUI]BB2#.?+15SC&=H SCGTJS14\SM8KE5[]0HHHI#,;5?"D.H.+C+
M1S#_ ):1-M;&",=QT.,XSC SCBH8]#NXR +MO+!'!BC+[1V+G.3C^(CKSBM^
MBJYY6L0Z<;W,+3_"$=I,+MI)9)%4A3*^[&<^P]3[